Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 73 for:    HYDROCHLOROTHIAZIDE AND LOSARTAN

Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02183701
Recruitment Status : Completed
First Posted : July 8, 2014
Last Update Posted : July 8, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Tracking Information
First Submitted Date  ICMJE July 7, 2014
First Posted Date  ICMJE July 8, 2014
Last Update Posted Date July 8, 2014
Study Start Date  ICMJE April 1998
Actual Primary Completion Date December 1998   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 7, 2014)
Change from baseline in 24-hour mean diastolic blood pressure measured by ABPM [ Time Frame: Baseline (Day 28 of run-in period) and day 42 ]
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: July 7, 2014)
  • Change from baseline in 24-hour mean systolic blood pressure measured by ABPM [ Time Frame: Baseline (Day 28 of run-in period) and day 42 ]
  • Change from baseline in systolic and diastolic blood pressures during other time periods during the 24-hour ABPM profile [ Time Frame: Baseline (Day 28 of run-in period) and day 42 ]
  • Change from baseline (Visit 2) in trough systolic and diastolic blood pressures measured by cuff sphygmomanometer [ Time Frame: Baseline (Day 28 of run-in period) and day 42 ]
  • Number of patient with of adverse events [ Time Frame: up to 10 weeks ]
  • Changes from baseline in pulse rate [ Time Frame: Baseline (Day 28 of run-in period) and day 42 ]
  • Changes in physical examination [ Time Frame: Screening and day 43 ]
  • Changes in laboratory parameters [ Time Frame: Screening and day 43 ]
  • Changes in 12-lead electrocardiogram (ECG) [ Time Frame: Baseline (Day 29 of run-in period) and day 43 ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension
Official Title  ICMJE A Prospective Randomised Open-Label Blinded Endpoint Trial Comparing Telmisartan 80 mg and Losartan 50 mg + Hydrochlorothiazide 12.5 mg (Fixed Dose Combination) in Patients With Mild-to-Moderate Essential Hypertension Using Ambulatory Blood Pressure Monitoring
Brief Summary The general aim and clinical objective of this trial is to determine the effect of telmisartan 80 mg compared to losartan 50 mg + HCTZ (Hydrochlorothiazide) 12.5 mg on reduction of blood pressure (BP) in patients with mild to moderate hypertension as assessed by 24 hour Ambulatory Blood Pressure Monitoring (ABPM) and trough sitting BP cuff measurements at the end of the treatment.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Hypertension
Intervention  ICMJE
  • Drug: Telmisartan
  • Drug: Losartan + Hydrochlorothiazide
  • Drug: Placebo
Study Arms  ICMJE
  • Experimental: Telmisartan
    4 weeks placebo run-in, 6-weeks fixed dose period
    Interventions:
    • Drug: Telmisartan
    • Drug: Placebo
  • Active Comparator: Losartan + Hydrochlorothiazide
    4 weeks placebo run-in, 6-weeks fixed dose period (Losartan 50 mg / HCTZ 12.5 mg)
    Interventions:
    • Drug: Losartan + Hydrochlorothiazide
    • Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 7, 2014)
715
Original Actual Enrollment  ICMJE Same as current
Study Completion Date  ICMJE Not Provided
Actual Primary Completion Date December 1998   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of ≥ 95 mmHg measured by manual cuff sphygmomanometer, on Visit 2 of the four-week placebo run-in period (baseline)
  • Mean seated systolic blood pressure ≥ 140 mmHg, measured by manual cuff at baseline (Visit 2)
  • A 24-hour mean diastolic blood pressure , measured by ABPM, of ≥ 85 mmHg evaluated at baseline (Visit 3)
  • Age 18 or older
  • Patient's written informed consent in accordance with GCP (Good Clinical Practice) and local legislation

Exclusion Criteria:

  • Pre-menopausal women (last menstruation ≤ 1 year prior to date of consent):

    • Who are not surgically sterile (hysterectomy, tubal ligation)
    • Who are NOT practising acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the trial. Acceptable methods of birth control include IUD (intrauterine device), oral, implantable or injectable contraceptives
    • Who have a positive urine pregnancy test
    • Who are nursing
  • Mean seated diastolic blood pressure (DBP) > 114 mmHg or mean seated systolic BP > 200 mmHg, by manual cuff
  • Any known hepatic and/or renal dysfunction as defined by the following laboratory parameters:

    • SGPT (serum glutamate pyruvate transaminase) (ALT) or SGOT (serum glutamate oxaloacetate transaminase) (AST) greater than two times the upper limit of normal
    • Serum creatinine > 1.8 mg/dl (or 159 µmol/l)
  • Clinically relevant hypokalemia
  • Known or suspected secondary hypertension
  • Known bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney.
  • Congestive heart failure (CHF) (NYHA (New York Heart Association) class CHF III-IV)
  • Unstable angina within the past 3 months; stable angina where a change in nitrate therapy (dose or frequency) during the run-in period was required
  • Stroke within the past 6 months prior to start of run-in period
  • Myocardial infarction or cardiac surgery within the past 3 months prior to start of run-in period
  • PTCA (percutaneous transluminal coronary angioplasty) within the past 3 months prior to start of run-in period
  • Previous history of angioedema
  • Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
  • Hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve
  • Patients with unstable insulin-dependent diabetes mellitus (risk of hypoglycemia or HbA1c ≥ 10 % in history within 6 months prior to start of run-in period)
  • Known drug or alcohol dependency within the past 6 months period prior to start of run-in period
  • Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
  • Patients receiving any investigational therapy within one month of signing the informed consent form
  • Known hypersensitivity to any component of the formulations
  • Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication
  • Concomitant use of lithium or cholestyramine or colestipol resins (potential drug interactions with HCTZ)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02183701
Other Study ID Numbers  ICMJE 502.257
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Boehringer Ingelheim
Study Sponsor  ICMJE Boehringer Ingelheim
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Boehringer Ingelheim
Verification Date July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP